Can oral mucositis be prevented in patients receiving chemotherapy?

Year 2012, Volume: 2 Issue: 4, 155 - 163, 30.01.2014

Nida Ünal Çubukçu , Sezgi Çınar

Abstract

Objective: The aim of this study was to determine the effects of using sodium bicarbonate solution, benzydamine hydrochloride solution and black mulberry syrup for oral care on oral mucositis in patients receiving chemotherapy. 

Method: The data of the present experimental study were obtained by the researcher using “Patient Observation Form”, “Oral Mucosa Evaluation Form”, and “Visual Analog Scale”. Ninety patients included in the study were divided into three groups. Group 1, Group 2 and Group 3 used oral care solutions of benzydamine hydrochloride, sodium bicarbonate, and black mulberry syrup, respectively. Frequency and average±standard deviation, chi-square, Fisher chi-square, Kolmogorov Smirnov, t-test, ANOVA variance analysis and Bonferroni multiple comparison tests were used for evaluation of the data. 

Results: Sociodemographic characteristics and smoking habits showed no significant difference. On the second interview, the number of patients without mucositis in group 3 was higher than that of the other groups. Throat pain points in Group 1 and Group 2 were increased whereas in Group 3 no change was monitored. Moreover, in Group 1, higher oral dryness points were marked. According to the Rotterdam symptom list, activity level of Group 1 was better than that of the other groups on the first interview, and physical disturbance of Group 2 was much more than that of the other groups on the second interview. 

Conclusion: Black mulberry syrup usage for avoiding oral mucositis, oral mucosal pain and oral dryness is recommended in patients receiving chemotherapy treatment.

Key words: Oral care, black mulberry syrup, chemotherapy, oral mucositis, sodium bicarbonate

Keywords

-

Kemoterapi alan kanserli hastalarda oral mukozitler önlenebilir mi?

Abstract

Amaç: Bu çalışmanın amacı, kemoterapi alan hastalarda ağız bakımı için sodyum bikarbonat solüsyonu, benzidamin hidroklorür solüsyonu ve karadut şurubu kullanımının oral mukozitlere etkisini belirlemektir. 

Yöntem: Araştırmanın verileri araştırmacı tarafından “Hasta İzlem Formu”, “Ağız Mukozası Değerlendirme Formu” ve “Ağrı Algı Skalası” kullanılarak toplandı. Araştırmanın örneklemini oluşturan 90 hasta üç gruba ayrıldı. Ağız bakım solüsyonu olarak Grup 1 “benzidamin hidroklorür”, Grup 2 “sodyum bikarbonat”, Grup 3 “karadut şurubu” kullandı. Verilerin değerlendirilmesinde frekans ve ortalama±standart sapma, ki-kare, Fisher ki-kare, Kolmogorov Smirnov, ANOVA, t-testi ve Bonferroni çoklu kıyaslama testleri kullanıldı. 

Bulgular: Üç grup arasında sosyodemografik özellikler ve sigara içme durumları açısından anlamlı fark bulunmadı. İkinci görüşmede; diğer gruplara göre Grup 3’de mukozit gelişmeyen hasta sayısı daha fazla oldu. Grup 1 ve Grup 2’de boğaz ağrısı sorunlarının arttığı, Grup 3’de değişiklik olmadığı, Grup 1’de ağız kuruluğu sorununun daha fazla olduğu belirlendi. Rotterdam semptom listesine göre; birinci görüşmede Grup 1’de aktivite düzeylerinin daha iyi olduğu, ikinci görüşmede ise Grup 2’de daha fazla fiziksel rahatsızlık yaşandığı belirlendi.

Sonuç: Kemoterapi alan hastalarda oral mukozitleri, ağız içi ağrıyı ve ağız kuruluğunu önlemek için karadut şurubu kullanılabilir.

Anahtar Kelimeler : Ağız bakımı, karadut şurubu, kemoterapi, oral mukozit, sodyum bikarbonat

Keywords

Ağız bakımı, karadut şurubu, kemoterapi, oral mukozit, sodyum bikarbonat

References

• Redding SW. Cancer therapy-related oral mucositis. J Dent Educ. 2005;69(8): 919-929.
• Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Oncology. 2003;17(12): 1767-1776.
• Filicko J, Lazarus HM, Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant. 2003;31: 1-10.
• Sonis ST, Elting LS, Keef D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004;100(9): 1995-2025.
• Alterio D, Jereczek-Fossa BA, Fiore MR, Piperno G, Ansarin M, Orecchia R. Cancer treatment-induced oral mucositis. Anticancer Research. 2007;27: 1105-1126.
• D’Hondt L, Lonchay C, André M, Canon JL. Oral mucositis induced by anticancer treatments: physiopathology and treatments. Therapeutics and Clinical Risk Management. 2006;2(2): 156-168.
• Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiology, chemotherapy and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head and Neck. 2004;1: 77-84.
• Brown CG, Yoder L. Stomatitis. An overview protecting the oral cavity during cancer treatment. Oncol Nursing Update. 2002;4: 20-23.
• Ilgenli T, Ören H, Uysal K. The acute effects of chemotherapy upon the oral cavity: prevention and management. Turkish J Cancer. 2001;31: 93-105.
• Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, Fraser CJ, Scarffe JH. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regiments and hematopoietic progenitor rescue. Br J Haematol. 2000;110: 292-299.
• Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34: 39-43.
• Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. More than a sore mouth: patients’ experience of oral mucositis. Oncol Nurs Forum. 2002;29: 1051-1057.
• Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52: 61-77.
• Peterson DE, Lalla RV. Oral mucositis: the new paradigms. Curr Opin Oncol. 2004;22: 318-322.
• Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenste EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;14: 1201-1207.
• Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncol. 1998;34:63-71.
• Scully C, Sonis S, Diz PD. Mucosal diseases series: Oral mucositis. Oral Diseases. 2006;12: 229-241.
• McGuire DB, Correa M, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14: 541-547.
• Miller M, Kearney N. Oral care for patients with cancer: a review of the literature. Cancer Nurs. 2001;24: 241-254.
• Eilers J. Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncology Nursing Forum. 2004;31(4): 13-23.
• Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: Are there new approaches? Cancer Nurs. 2004;27: 183-205.
• Mead GM. Management of oral mucositis associated with cancer chemotherapy. The Lancet. 2002;359: 815-816.
• Papadeas E, Naxakis S, Riga M, Kalofonos C. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: A randomized controlled study. European Journal of Oncology Nursing. 2007;11: 60-65.
• Rubenstein EB, Peterson DE, Schubert M. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100 (Suppl. 9): 2026-2046.
• Epstein JB, Truelove EL, Oien H, Allison C, Le ND, Epstein MS. Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. Oral Oncology, 2001;37: 632- 637.
• Haes JCM, Van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62: 1034-1038.
• Can G, Durna Z, Aydiner A. Assessment of fatigue in and care needs of Turkish women with breast cancer. Cancer Nursing. 2004;27(2): 153-161.
• Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of saforis for preventing and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2007;109(2): 322-331.
• Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head and Neck. 2003;25: 1057-1070.
• Wright J, Feld R, Knox J. Chemotherapy-induced oral mucositis: new approaches to prevention and management. Exp Opin Drug Saf. 2005;4: 193-200.
• Turhal NS, Erdal S, Karaçay S. Efficacy of treatment to relieve mucositis- induced discomfort. Support Care Cancer. 2000;8: 55-58.
• Epstein JB, Silverman S, Pagglarino D, Crockett S, Schubert M, Senzer N, Lockhart B, Gallagher M, Peterson D, Leveque F. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis. Cancer. 2001;92: 875-85.
• Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology. 2010;21 (Suppl. 5): 261-265.
• Yigit N, Yigit D, Ozgen U, Aktas AE. Karadut (Morus nigra L.)’nun antikandidal aktivitesi. Türk Mikrobiyol Cem Derg. 2007;37(3): 169- 173.
• Cheng KK-F. Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. Journal of Clinical Nursing. 2007;16: 2114-2121.